Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C
Summary Hepatic CD1d‐restricted and natural killer T‐cell populations are heterogeneous. Classical ‘type 1′ α‐galactosylceramide‐reactive CD1d‐restricted T cells express ‘invariant’ TCRα (‘iNKT’). iNKT dominating rodent liver are implicated in inflammation, including in hepatitis models. Low levels...
Saved in:
Published in: | Journal of viral hepatitis Vol. 20; no. 8; pp. 556 - 565 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Blackwell Publishing Ltd
01-08-2013
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Summary
Hepatic CD1d‐restricted and natural killer T‐cell populations are heterogeneous. Classical ‘type 1′ α‐galactosylceramide‐reactive CD1d‐restricted T cells express ‘invariant’ TCRα (‘iNKT’). iNKT dominating rodent liver are implicated in inflammation, including in hepatitis models. Low levels of iNKT are detected in human liver, decreased in subjects with chronic hepatitis C (CHC). However, high levels of human hepatic CD161±CD56± noninvariant pro‐inflammatory CD1d‐restricted ‘type 2′ T cells have been identified in vitro. Unlike rodents, healthy human hepatocytes only express trace and intracellular CD1d. Total hepatic CD1d appears to be increased in CHC and primary biliary cirrhosis. Direct ex vivo analysis of human intrahepatic lymphocytes (IHL), including matched ex vivo versus in vitro expanded IHL, demonstrated detectable noninvariant CD1d reactivity in substantial proportions of HCV‐positive livers and significant fractions of HCV‐negative livers. However, α‐galactosylceramide‐reactive iNKT were detected only relatively rarely. Liver CD1d‐restricted IHL produced IFNγ, variable levels of IL‐10 and modest levels of Th2 cytokines IL‐4 and IL‐13 ex vivo. In a novel FACS assay, a major fraction (10–20%) of hepatic T cells rapidly produced IFNγ and up‐regulated activation marker CD69 in response to CD1d. As previously only shown with murine iNKT, noninvariant human CD1d‐specific responses were also augmented by IL‐12. Interestingly, CD1d was found selectively expressed on the surface of hepatocytes in CHC, but not those CHC subjects with history of alcohol usage or resolved CHC. In contrast to hepatic iNKT, noninvariant IFNγ‐producing type 2 CD1d‐reactive NKT cells are commonly detected in CHC, together with cognate ligand CD1d, implicating them in CHC liver damage. |
---|---|
Bibliography: | BMS 'Freedom to Discover' Award VA Merit Award - No. U19 AI 1066328 ark:/67375/WNG-7WR9TPFW-6 Cooperative Human Tissue Network and National Disease Research Interchange - No. 5U42-RR006042; No. DK066917; No. CA143748; No. AI066313; No. AI053481 istex:01A5F7BF916F7AB20A50A8925984B93A68AE5F96 ArticleID:JVH12081 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 AVEO Pharmaceuticals, Cambridge, MA. Vertex Pharmaceuticals, Cambridge, MA. Current addresses: Surgery, Kasumigaura Medical Center, Ibaraki, Japan. Medical Oncology, Vrije Universiteit, Amsterdam. |
ISSN: | 1352-0504 1365-2893 |
DOI: | 10.1111/jvh.12081 |